



Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 1.01. Other Events.

As previously announced, on November 14, 2018, we entered into a binding term sheet with Elliott Management Corporation for a \$7.5 million 3-year convertible debt facility. As disclosed in our November 14, 2018 quarterly conference call, the term sheet required us to amend, and on December 19, 2018, we amended the following warrants held by Elliott Associates, L.P. and its affiliates to reduce the exercise price of each warrant to \$0.001 per share: warrants issued in May 2013 to purchase up to an aggregate of 500,000 shares of our common stock with a pre-amendment exercise price of \$0.65 per share and an expiration date of May 30, 2019; and warrants issued in October 2013 to purchase up to an aggregate of 750,000 shares of our common stock with a pre-amendment exercise price of \$0.90 per share and an expiration date of October 22, 2019. The reductions in the exercise prices will be rescinded in the event (i) we use our best efforts to consummate the transactions contemplated by and on the terms set forth in the term sheet, and (ii) notwithstanding such efforts, such transactions are not consummated. We are negotiating the definitive documents for the convertible debt facility.



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: December 21, 2018 By: /s/ Robert W. Cook  
Name: Robert W. Cook  
Title: Chief Financial Officer